---
title: 'Mitigating inequity: ethically prioritizing patients to CAR T-cell therapy'
date: '2023-08-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37540818/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230805180705&v=2.17.9.post6+86293ac
source: Blood
description: Manufacturing capacity and institutional infrastructure to deliver CAR
  T-cell therapies (CAR-T) are pressured to keep pace with the growing number of approved
  products and expanding eligible patient population for this potentially life-saving
  therapy. Consequently, many cell therapy programs must make difficult decisions
  about which patient should get the next available treatment slot. This situation
  requires an ethical framework to ensure fair and equitable decision-making. In this
  ...
disable_comments: true
---
Manufacturing capacity and institutional infrastructure to deliver CAR T-cell therapies (CAR-T) are pressured to keep pace with the growing number of approved products and expanding eligible patient population for this potentially life-saving therapy. Consequently, many cell therapy programs must make difficult decisions about which patient should get the next available treatment slot. This situation requires an ethical framework to ensure fair and equitable decision-making. In this ...